Author:
Kempf Emmanuelle,Bogaerts Jan,Lacombe Denis,Liu Lifang
Reference30 articles.
1. The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001;Lichtenberg;Int J Health Care Finance Econ,2005
2. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015;Vivot;Ann Oncol Off J Eur Soc Med Oncol,2017
3. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2);Allemani;Lancet (London, England),2015
4. Why do some countries approve a cancer drug and others don't?;Pujolras;J Cancer Policy,2015
5. NICE recommends kidney cancer drug it previously rejected on cost grounds;Mayor;BMJ,2009
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献